Connect Biopharma Holdings Ltd. (CNTB)
0.7287
0.00 (0.00%)
USD |
NASDAQ |
Nov 06, 16:00
0.73
0.00 (0.00%)
After-Hours: 20:00
Connect Biopharma Holdings Research and Development Expense (Quarterly) : 16.27M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 16.27M |
| March 31, 2026 | 15.03M |
| December 31, 2025 | 11.28M |
| Date | Value |
|---|---|
| September 30, 2025 | 11.11M |
| June 30, 2025 | 8.773M |
| March 31, 2025 | 6.633M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Anavex Life Sciences Corp. | -4.705M |
| Vaxcyte, Inc. | 270.33M |
| Foghorn Therapeutics, Inc. | 18.32M |
| Caribou Biosciences, Inc. | 21.35M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |